AstraZeneca’s Imfinzi-Based Regimen Shows Significant Benefit in Early Gastric and GEJ Cancers in Phase III MATTERHORN Trial AstraZeneca has reported highly promising results from its Phase III MATTERHORN trial, showcasing the potential of its immunotherapy drug Imfinzi (durvalumab) to transform…
Roche Reports Promising Two-Year Results for Fenebrutinib in Relapsing Multiple Sclerosis, Maintaining Disease Control and Halting Disability Progression Roche has released encouraging new long-term data from its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, in the treatment of relapsing multiple…
Merck Reports Encouraging Early Data for Investigational KRAS G12C Inhibitor MK-1084 in Phase 1 Trial for Advanced Colorectal and Lung Cancers Merck known as MSD outside the United States and Canada, has announced promising early results from its ongoing KANDLELIT-001…
AbbVie and the Chicago Cubs Launch Multi-Year “Striking Out Cancer” Campaign to Support Cancer Awareness and Research In a bold and heartfelt effort to turn America’s favorite pastime into a platform for cancer advocacy, AbbVie,a global biopharmaceutical company headquartered in…
Teva Embarks on Acceleration Phase of “Pivot to Growth” Strategy at 2025 Innovation & Strategy Day, Signaling Renewed Focus on Biopharmaceutical Leadership and Long-Term Shareholder Value Teva Pharmaceutical Industries Ltd.one of the world’s leading manufacturers of generic and specialty medicines,…
China Accepts New Drug Application for Shionogi’s Naldemedine to Treat Opioid-Induced Constipation Shionogi & Co., Ltd., a leading Japanese pharmaceutical company headquartered in Osaka, has announced a key regulatory milestone for its gastrointestinal therapeutic, naldemedine tosilate. The New Drug Application…
Astellas Secures Global Rights to Evopoint’s Promising CLDN18.2-Targeting Antibody-Drug Conjugate XNW27011 in Strategic Oncology Expansion In a strategic move that reinforces its commitment to precision oncology, Astellas Pharma Inc. has entered into an exclusive license agreement with Evopoint Biosciences Co.,…
Intellia Grapples with Safety Questions in ATTR Gene Editing Trial Amid Broader Sector Scrutiny Intellia Therapeutics’ stock took a steep dive Thursday morning, shedding approximately 26% of its value after the company disclosed a serious adverse event in its ongoing…
CVS Health Files Federal Lawsuit to Halt Arkansas’ Act 624, Citing Harm to Patients, Jobs, and Healthcare Access On May 29, 2025, CVS Health® filed a federal lawsuit seeking to overturn Arkansas’ controversial Act 624, a newly enacted law that…
Beyfortus Shows Stronger Public Health Impact Than Maternal RSV Vaccine in Landmark Real-World Comparison In a pivotal step forward for infant respiratory health, new real-world data from an immunization program in Spain reveal that Beyfortus® (nirsevimab), a long-acting monoclonal antibody…
Member States Officially Endorse World Prematurity Day as a Global Health Campaign at the 78th World Health Assembly At the recently concluded 78th World Health Assembly (WHA), a historic and decisive step was taken by the global health community: Member…
WHO Launches Comprehensive Framework Addressing the Intersection of Climate Change and Tuberculosis In a decisive move to confront two of the world’s most pressing public health challenges, the World Health Organization (WHO) has released a comprehensive new framework highlighting the…
